Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2e)-((4r)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)(1h-imidazol-1-yl)acetonitrile
2. 4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene-1-imidazolylacetonitrile
3. Lulicon
4. Nnd 502
5. Nnd-502
6. Nnd502
1. 187164-19-8
2. Lulicon
3. Nnd-502
4. Luzu
5. Pr-2699
6. (2e)-2-[(4r)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile
7. Nnd 502
8. Re91an4s8g
9. Ncgc00182704-01
10. Ncgc00182704-02
11. Chebi:34825
12. (2e)-2-[(4r)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-yl-acetonitrile
13. (r,e)-2-(4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)-2-(1h-imidazol-1-yl)acetonitrile
14. Ncgc00182704-03
15. 2-[(2e,4r)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-(1h-imidazol-1-yl)acetonitrile
16. Dsstox_cid_28533
17. Dsstox_rid_82805
18. Dsstox_gsid_48607
19. (-)-(e)-((4r)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)(1h-imidazol-1-yl)acetonitrile
20. Luliconazole [inn]
21. Nnd502
22. Cas-187164-19-8
23. Luliconazole [usan:inn]
24. Unii-re91an4s8g
25. 4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene-1-imidazolylacetonitrile
26. Lulicon (tn)
27. Imidazole Antimycotic
28. Luzu (tn)
29. Luliconazole [mi]
30. Luliconazole [jan]
31. Luliconazole [usan]
32. Luliconazole [vandf]
33. Luliconazole [mart.]
34. Luliconazole [who-dd]
35. Schembl342362
36. Gtpl7366
37. Luliconazole (jan/usan/inn)
38. Chembl2105689
39. Dtxsid3048607
40. Luliconazole, >=98% (hplc)
41. Luliconazole [orange Book]
42. Zinc3929486
43. Tox21_112942
44. Tox21_112974
45. Mfcd00953915
46. S4258
47. Akos015897320
48. Tox21_112974_1
49. Am84645
50. Bcp9000863
51. Ccg-268075
52. Cs-0587
53. Db08933
54. Ds-3278
55. (2e)-((4r)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)(1h-imidazol-1-yl)acetonitrile
56. Ncgc00182704-08
57. Hy-14283
58. L0306
59. Sw219226-1
60. D01980
61. 164l198
62. A813122
63. Sr-01000945039
64. Sr-01000945039-1
65. Q15624030
66. 1h-imidazole-1-acetonitrile, Alpha-((4r)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)-, (alphae)-
| Molecular Weight | 354.3 g/mol |
|---|---|
| Molecular Formula | C14H9Cl2N3S2 |
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 352.9614950 g/mol |
| Monoisotopic Mass | 352.9614950 g/mol |
| Topological Polar Surface Area | 92.2 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 476 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Luzu |
| PubMed Health | Luliconazole (On the skin) |
| Drug Classes | Antifungal |
| Drug Label | LUZU (luliconazole) Cream, 1% contains 1% luliconazole, an azole antifungal agent, in a white cream for topical application.Luliconazole is (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile. Its structural formu... |
| Active Ingredient | Luliconazole |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 1% |
| Market Status | Prescription |
| Company | Medicis |
| 2 of 2 | |
|---|---|
| Drug Name | Luzu |
| PubMed Health | Luliconazole (On the skin) |
| Drug Classes | Antifungal |
| Drug Label | LUZU (luliconazole) Cream, 1% contains 1% luliconazole, an azole antifungal agent, in a white cream for topical application.Luliconazole is (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile. Its structural formu... |
| Active Ingredient | Luliconazole |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 1% |
| Market Status | Prescription |
| Company | Medicis |
Luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by Trichophyton rubrum and Epidermophyton floccosum, specifically tinea pedis, cruris, and corporis.
FDA Label
Luliconazole kills the organisms Trichophyton rubrum and Epidermophyton floccosum, most likely by altering their fungal cell membranes.
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
D - Dermatologicals
D01 - Antifungals for dermatological use
D01A - Antifungals for topical use
D01AC - Imidazole and triazole derivatives
D01AC18 - Luliconazole
Absorption
Although luliconazole is administered topically, clinical studies have shown that after the first dose in patients with tina pedis, a maximum plasma concentration of 0.40 0.76 ng/mL (mean SD) occurred in 16.9 9.39 hours (mean SD).
Route of Elimination
The route of elimination of luliconazole has yet to be determined.
Volume of Distribution
The volume of distribution was not quantified.
Clearance
The clearance of luliconazole has yet to be determined.
The metabolism of luliconazole has yet to be determined.
The half life of luliconazole has yet to be determined.
The exact mechanism of action for luliconazole's anti-fungal activity is still not known, but luliconazole is thought to inhibit the enzyme lanosterol demethylase. Lanosterol demethylase is needed for the synthesis of ergosterol, which is a major component of the fungus cell membranes.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Solubilizers
Emulsifying Agents
Surfactant & Foaming Agents
Thickeners and Stabilizers
Film Formers & Plasticizers
Parenteral
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
11
PharmaCompass offers a list of Luliconazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Luliconazole manufacturer or Luliconazole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Luliconazole manufacturer or Luliconazole supplier.
PharmaCompass also assists you with knowing the Luliconazole API Price utilized in the formulation of products. Luliconazole API Price is not always fixed or binding as the Luliconazole Price is obtained through a variety of data sources. The Luliconazole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Luliconazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Luliconazole, including repackagers and relabelers. The FDA regulates Luliconazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Luliconazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Luliconazole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Luliconazole supplier is an individual or a company that provides Luliconazole active pharmaceutical ingredient (API) or Luliconazole finished formulations upon request. The Luliconazole suppliers may include Luliconazole API manufacturers, exporters, distributors and traders.
click here to find a list of Luliconazole suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Luliconazole DMF (Drug Master File) is a document detailing the whole manufacturing process of Luliconazole active pharmaceutical ingredient (API) in detail. Different forms of Luliconazole DMFs exist exist since differing nations have different regulations, such as Luliconazole USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Luliconazole DMF submitted to regulatory agencies in the US is known as a USDMF. Luliconazole USDMF includes data on Luliconazole's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Luliconazole USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Luliconazole suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Luliconazole Drug Master File in Japan (Luliconazole JDMF) empowers Luliconazole API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Luliconazole JDMF during the approval evaluation for pharmaceutical products. At the time of Luliconazole JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Luliconazole suppliers with JDMF on PharmaCompass.
A Luliconazole written confirmation (Luliconazole WC) is an official document issued by a regulatory agency to a Luliconazole manufacturer, verifying that the manufacturing facility of a Luliconazole active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Luliconazole APIs or Luliconazole finished pharmaceutical products to another nation, regulatory agencies frequently require a Luliconazole WC (written confirmation) as part of the regulatory process.
click here to find a list of Luliconazole suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Luliconazole as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Luliconazole API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Luliconazole as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Luliconazole and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Luliconazole NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Luliconazole suppliers with NDC on PharmaCompass.
Luliconazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Luliconazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Luliconazole GMP manufacturer or Luliconazole GMP API supplier for your needs.
A Luliconazole CoA (Certificate of Analysis) is a formal document that attests to Luliconazole's compliance with Luliconazole specifications and serves as a tool for batch-level quality control.
Luliconazole CoA mostly includes findings from lab analyses of a specific batch. For each Luliconazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Luliconazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Luliconazole EP), Luliconazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Luliconazole USP).
